A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with mild Crohn's disease, offering a potential pathway toward more personalized ...
A phase 2 study of intravenous pembrolizumab and intratumorally injected autologous dendritic cells (DCs) in refractory colorectal cancer (CRC). This is an ASCO Meeting Abstract from the 2025 ASCO ...